Meet The Professors VOL 4, ISSUE 1

Select publications

Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer. San Antonio Breast Cancer Symposium 2004;Abstract 6052.

Davidson NE et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: Results from INT 0101 (E5188). J Clin Oncol 2005;23(25):5973-82. Abstract

Davis AL et al. Chemotherapy-induced amenorrhea from adjuvant breast cancer treatment: The effect of the addition of taxanes. Clin Breast Cancer 2005;6(5):421-4. Abstract

Forward DP et al. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 2004;90(3):590-4. Abstract

Kauff ND et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. J Natl Cancer Inst 2005;97(18):1382-4. Abstract

Klijn JG et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 2001;19(2):343-53. Abstract

Klijn JG et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 2000;92(11):903-11. Abstract

Kramer JL et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 2005; 23(34):8629-35. Abstract

Nelson HD et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: Systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005;143(5):362-79. Abstract

Parulekar WR et al; National Cancer Institute of Canada Clinical Trials Group. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study/ — NCIC CTG MA.5. J Clin Oncol 2005;23(25):6002-8. Abstract

Petrek JA et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 2006;24(7):1045-51. Abstract

Vanhuyse M et al. Chemotherapy-induced amenorrhea: Influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients. Ann Oncol 2005;16(8):1283-8. Abstract

Young O et al. Randomized pre-operative study of 750mg of fulvestrant and 20mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2005;Abstract 5084.